Search results for "TUMORS"

showing 10 items of 1138 documents

Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.

2011

OBJECTIVES To investigate cancer-related outcomes and prognostic factors of papillary renal cell carcinoma (pRCC) in a large multicentre data set. Oncological outcome and prognostic factors of pRCC have been limitedly evaluated in comparison with the most common RCC subtype, clear cell RCC. PATIENTS AND METHODS From a multicentre retrospective database, including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007, 577 patients with pRCC were identified. Univariable and multivariable Cox regression models were performed to identify prognostic factors predictive of recurrence-free survival (RFS) and cancer-specific survival (CSS) after surge…

Malerenal cell carcinomaTime FactorsPapillary renal cell carcinoma; Prognostic factorsPrognosiFEATURESkidney cancer; papillaryrenal cell carcinoma; papillary adenocarcinoma; prognostic factorspapillary renal cell carcinomaNephrectomyCLASSIFICATIONFollow-Up Studiecancer-specific survivalpapillaryRisk FactorsRetrospective StudieCause of DeathPrevalenceHumansrecurrence-free survivalprognostic factorCarcinoma Renal CellTYPE-1Proportional Hazards ModelsRetrospective StudiesNeoplasm StagingAcademic Medical Centerspapillary adenocarcinomaRisk Factorkidney cancerKidney Neoplasmprognostic factorsMiddle AgedPrognosisTUMORSKidney NeoplasmsHISTOLOGIC SUBTYPESPrognostic factors in a large multi-institutional series of papillary renal cell carcinoma.Survival RateAcademic Medical CenterItalySURVIVALProportional Hazards ModelFemaleprognostic factors; papillary renal cell carcinoma; recurrence-free survival; cancer-specific survivalFollow-Up StudiesHuman
researchProduct

Pan-cancer analysis of whole genomes

2020

Publisher's version (útgefin grein)

Maletert promoter mutationsCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]DNA Mutational AnalysisNormal tissuesystematic analysisGermlineTranscriptome0302 clinical medicineAetiologyCàncerCellular SenescenceCancer0303 health sciencesdna-damageMassive parallel sequencingPan cancerREARRANGEMENTSHigh-Throughput Nucleotide SequencingGenomicsSciences bio-médicales et agricolesTelomereCOMPREHENSIVE3. Good healthTERT PROMOTER MUTATIONSsignatures030220 oncology & carcinogenesisScience & Technology - Other TopicsErfðarannsóknirHuman:Informàtica::Aplicacions de la informàtica::Bioinformàtica [Àrees temàtiques de la UPC]EvolutionRNA SplicingGenomicsArticleEvolution MolecularStructural variationRC025403 medical and health sciencesSDG 3 - Good Health and Well-beingGeneticgenomicsSYSTEMATIC ANALYSISGeneticsGenomics--Databases.HumansGenetic TestingMolecular BiologySIGNATURESWhole genome sequencing1000 MultidisciplinaryChromothripsisScience & TechnologyRC0254 Neoplasms. Tumors. Oncology (including Cancer)Information DisseminationResearchInstitutes_Networks_Beacons/mcrcPreventionBiology and Life SciencesMolecularOncogenesCloud Computingmedicine.diseaseGenòmicaCompute cloudsMutation570 Life sciences; biologyCOMPREHENSIVE CHARACTERIZATIONGenèticaWhole Genome Sequencing--methodsBackground informationDNA Mutational Analysis ; Evolution ; Genetic / genetics ; Genome ; Genomics ; Germ-Line Mutation / genetics ; High-Throughput Nucleotide Sequencing ; Human / genetics ; Humans ; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes ConsortiumMedizinGenomeWhole-genomeGenome mappingNeoplasms2.1 Biological and endogenous factorsPromoter Regions GeneticCàncer -- Aspectes genèticsTelomeraseGeneticsWomen's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17]MultidisciplinaryChromothripsisGenomeManchester Cancer Research Centregenomics cancer profiling3rd-DAS10124 Institute of Molecular Life SciencesWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]Multidisciplinary SciencesParallel sequencingICGC/TCGA Pan-Cancer Analysis of Whole Genomes ConsortiumFemaleprofilingMedical GeneticsEngineering sciences. TechnologyBiotechnologyGeneral Science & TechnologyThe Cancer Genome Atlas610 Medicine & healthComputational biologyQH426 GeneticsBiologyConsortium of the International Cancer Genome ConsortiumPromoter RegionsGermline mutationPan-cancer analysisKrabbameinsrannsóknirmedicinecancerddc:610QH426Germ-Line MutationMedicinsk genetikKrabbamein030304 developmental biologyCell ProliferationLANDSCAPEGenome Humancomprehensive characterizationPan-cancer analysis of whole genomesPoint mutationHuman GenomeCancerReproducibility of ResultsSOMATIC MUTATIONSEVOLUTIONCancer sequencing Chromothripsis telomereDNA-DAMAGEMutagenesisPATTERNS3111 BiomedicineCHARACTERIZATION
researchProduct

Red-Light-Controlled Release of Drug-Ru Complex Conjugates from Metallopolymer Micelles for Phototherapy in Hypoxic Tumor Environments

2018

Traditional photodynamic phototherapy is not efficient for anticancer treatment because solid tumors have a hypoxic microenvironment. The development of photoactivated chemotherapy based on photoresponsive polymers that can be activated by light in the “therapeutic window” would enable new approaches for basic research and allow for anticancer phototherapy in hypoxic conditions. This work synthesizes a novel Ru‐containing block copolymer for photoactivated chemotherapy in hypoxic tumor environment. The polymer has a hydrophilic poly(ethylene glycol) block and a hydrophobic Ru‐containing block, which contains red‐light‐cleavable (650–680 nm) drug–Ru complex conjugates. The block copolymer se…

Materials scienceBiocompatibility02 engineering and technology010402 general chemistry01 natural sciencesMicelleBiomaterialschemistry.chemical_compoundElectrochemistryCopolymerrutheniumchemistry.chemical_classificationhypoxic tumorsPolymermetallopolymers021001 nanoscience & nanotechnologyCondensed Matter PhysicsControlled release0104 chemical sciencesElectronic Optical and Magnetic Materialsred lightchemistryCancer cellBiophysics0210 nano-technologyEthylene glycolConjugatephototherapy
researchProduct

Fibroma osificante maxilar: presentación de un caso y revisión de la literatura

2004

Existe un conjunto de procesos que han sido denominados genéricamente lesiones fibroóseas benignas, entre las que se encuentran la displasia fibrosa, la osteomielitis esclerosante y el fibroma osificante o cementificante. Todos estos procesos tienen un estroma fibroblástico vascular y producen una matriz calcificada que comprende desde el hueso hasta el cemento. El fibroma osificante se caracteriza por presentar un crecimiento y una tumefacción deformante de evolución lenta que generalmente aparece en la mandíbula y puede producir desplazamiento dentario precoz. Desde el punto de vista radiológico aparece generalmente como un área radiotransparente unilocular bien definida y demarcada o com…

Maxil·larsJawsOdontologíaMalalties de la bocaFibromas:CIENCIAS MÉDICAS [UNESCO]OdontologiaCiencias de la saludFibromeslesiones fibroóseas benignasMalalties dels ossosMouth diseasesDentistryUNESCO::CIENCIAS MÉDICASFibroma osificanteBone diseasesfibroma cemento-osificanteTumors
researchProduct

Exposición a factores ambientales y riesgo de tumores en el sistema nervioso central en niños: revisión sistemática y metaanálisis

2014

Se analiza el riesgo de tumores en el sistema nervioso central en niños en relación con la exposición a factores ambientales como radiaciones (ionizantes, no ionizantes), sustancias químicas (pesticidas, productos de belleza, contaminantes atmosféricos) y alimentos. Se realizó una revisión sistemática y un metaanálisis con estudios identificados en la búsqueda de PubMed (1987-2013). Los resultados obtenidos a partir de los valores de OR muestran que el riesgo de tumores en el sistema nervioso central en niños se asocia significativamente con la exposición de los padres y que el periodo prenatal es una ventana crítica para varios de los factores ambientales considerados. Aunque la fracción d…

Medicina preventivaTumors en els infantsAire ContaminacióTumorsReaccions químiques
researchProduct

The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma …

2021

Inhibidor de KIF11; Terapias dirigidas; Metástasis Inhibidor de KIF11; Teràpies dirigides; Metàstasi KIF11 inhibitor; Targeted therapies; Metastasis In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies. The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/013…

Medicine (General)Neuroblastoma - Tractament:neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma [ENFERMEDADES]Metastatic neuroblastomaMedicació oralMedicaments antineoplàstics - Ús terapèutic:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Medicine (miscellaneous)Administration OralKinesinsAntineoplastic Agents:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Letter to Editor:Neoplasms::Neoplasms by Histologic Type::Neoplasms Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms Neuroepithelial::Neuroectodermal Tumors Primitive::Neuroectodermal Tumors Primitive Peripheral::Neuroblastoma [DISEASES]MiceNeuroblastomaR5-920Cell Line Tumor:terapéutica::farmacoterapia::vías de administración de medicamentos::administración oral [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]MedicineAnimalsHumansAntitumor activityPrimary (chemistry)business.industry:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS]Disease Models Animal:Therapeutics::Drug Therapy::Drug Administration Routes::Administration Oral [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Cancer researchMolecular Medicine:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS]businessClinical and Translational Medicine
researchProduct

Expression of selected molecular factors in two types of endometrial cancer

2021

BACKGROUND Endometrial cancers (EC) are a heterogeneous group of malignant neoplasms differing in etiology, clinical-pathological features and prognosis. OBJECTIVES To determine the differences between the expression of selected molecular factors and find connections between them in order to isolate possible biomarkers influencing treatment options. MATERIAL AND METHODS The investigated data involved archival histological preparations obtained from uterine EC samples taken from 137 patients, treated surgically between 2007 and 2014. The immunohistochemical Dako EnVisionTM Flex+ method was applied. RESULTS The expression of ERβ, MLH1 and BRCA1 was lower in ECI than in ECII patients. The ERα …

Medicine (miscellaneous)BiologyMLH1General Biochemistry Genetics and Molecular BiologyMYH9AndrologyInternal MedicinemedicineHumansPharmacology (medical)Stage (cooking)Grading (tumors)Genetics (clinical)Neoplasm StagingHeterogeneous groupFAKEndometrial cancerAdvanced stageTreatment optionsBAPPrognosismedicine.diseaseEndometrial Neoplasmsendometrial cancerReviews and References (medical)ImmunohistochemistryFemaleAdvances in Clinical and Experimental Medicine
researchProduct

Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1

2021

Medulloblastoma is the most common malignant brain tumor in children. Immunotherapy is yet to demonstrate dramatic results in medulloblastoma, one reason being the low rate of mutations creating new antigens in this entity. In tumors with low mutational burden, gene fusions may represent a source of tumor-specific neoantigens. Here, we reviewed the landscape of fusions in medulloblastoma and analyzed their predicted immunogenicity. Furthermore, we described a new in-frame fusion protein identified by RNA-Seq. The fusion involved two genes on chromosome 2 coding for the enhancer of polycomb homolog 2 (EPC2) and GULP PTB domain containing engulfment adaptor 1 (GULP1) respectively. By qRT-PCR …

MedulloblastomafusionCancer Researchmedulloblastoma; EPC2; GULP1; fusionImmunogenicityIn silicoGULP1Neoplasms. Tumors. Oncology. Including cancer and carcinogensBiologymedulloblastomamedicine.diseaseFusion proteinEPC2OncologyAntigenCancer researchmedicineCytotoxic T cellEnhancerRC254-282CD8Cancers
researchProduct

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

2012

T lymphocytes are often induced naturally in melanoma patients and infiltrate tumors. Given that gamma delta T cells mediate antigen-specific killing of tumor cells, we studied the representation and the in vitro cytokine production and cytotoxic activity of tumor infiltrating gamma delta T cells from 74 patients with primary melanoma. We found that gamma delta T cells represent the major lymphocyte population infiltrating melanoma, and both V delta 1(+) and V delta 2(+) cells are involved. The majority of melanoma-infiltrating gamma delta cells showed effector memory and terminally-differentiated phenotypes and, accordingly, polyclonal gamma delta T cell lines obtained from tumor-infiltrat…

MelanomasCytotoxicity ImmunologicMaleRENAL-CELL CARCINOMA OVERCOMING IMMUNOLOGICAL-TOLERANCE METASTATIC MELANOMA TUMOR-CELLS PHASE-I MEVALONATE PATHWAY TARGETING CTLA-4 LYMPH-NODES IMMUNOTHERAPY CANCERAnatomy and PhysiologySkin NeoplasmsTUMOR-CELLSLymphocytemedicine.medical_treatmentT-LymphocytesSettore MED/19 - Chirurgia PlasticaTARGETING CTLA-4Interleukin 21T-Lymphocyte SubsetsImmune PhysiologyMETASTATIC MELANOMACytotoxic T cellIL-2 receptorSkin TumorsMelanomaOVERCOMING IMMUNOLOGICAL-TOLERANCEAged 80 and overMultidisciplinaryT CellsMelanomaMalignant MelanomaQRReceptors Antigen T-Cell gamma-deltaMiddle AgedCANCERPHASE-Imedicine.anatomical_structureCytokinePhenotypeOncologyCytokinesMedicineFemaleResearch ArticleTumor ImmunologyAdultScienceT cellImmune CellsImmunologyMalignant Skin NeoplasmsDermatologyBiologyImmunophenotypingImmune systemLymphocytes Tumor-InfiltratingmedicineHumansIMMUNOTHERAPYBiologyAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleLYMPH-NODESCancers and NeoplasmsImmunologic Subspecialtiesmedicine.diseaseImmune SystemImmunologyOVERCOMING IMMUNOLOGICAL-TOLERANCE; METASTATIC MELANOMA; TUMOR-CELLS; PHASE-I; MEVALONATE PATHWAY; TARGETING CTLA-4; LYMPH-NODES; IMMUNOTHERAPY; CANCERClinical ImmunologyImmunologic MemoryMEVALONATE PATHWAYPLoS ONE
researchProduct

Cell Systems Bioelectricity: How Different Intercellular Gap Junctions Could Regionalize a Multicellular Aggregate

2021

Simple Summary Electric potential patterns across tissues are instructive for development, regeneration, and tumorigenesis because they can influence transcription, migration, and differentiation through biochemical and biomechanical downstream processes. Determining the origins of the spatial domains of distinct potential, which in turn decide anatomical features such as limbs, eyes, brain, and heart, is critical to a mature understanding of how bioelectric signaling drives morphogenesis. We studied theoretically how connexin proteins with different voltage-gated gap junction conductances can maintain multicellular regions at distinct membrane potentials. We analyzed a minimal model that i…

Membrane potentialCancer ResearchChemistryelectric potential patternsCellGap junctioncell bioelectricityConnexinNeoplasms. Tumors. Oncology. Including cancer and carcinogension channelsArticleMulticellular organismtumorigenesismedicine.anatomical_structureElectrical SynapsesOncologyEvolutionary developmental biologymedicineintercellular gap junctionsNeuroscienceIon channelRC254-282Cancers
researchProduct